[Clinical trial of the Bulgarian preparations, flatugel and almagel-neo in duodenal ulcer].
The therapeutic effect of four new variants of the preparation Almagel was studied in 100 patients with duodenal ulcer (25 patients in each group were examined)---Flatugel, Flatugel A, Almagel-Neo. The pains, with the treatment faded away in 60 to 68% and abated in 25 to 32% of the treated in the separate groups. As compared with the control group, the symptom constipation was influenced in a higher per cent by the new preparations, explained by the twice higher dose of magnesium hydroxide in the new almagel derivatives. Flatugel A and almagel A-neo had the best upon vomiting, due to the anesthesin, contained in them. In half of the patients, the clinical symptoms disappeared during the first week after the initiation of the treatment and after its termination the clinical manifestations remained unaffected in only 8% of the patients. After the 20-day treatment with the new modifications of almagel, the ulcer niche disappeared in 25-29% and its dimensions were reduced in 30-50%. No significant differences were established as regards the effect upon the rest of the clinical symptoms and ulcer niche among the new preparations themselves and each separate preparations as compared with the control group. The new almagel modifications show a tendency of reduction of gastric secretion and acidity 12 hours after the termination of the treatment as compared with the same prior to treatment, but the differences are statistically insignificant. The new variants of almagel have a pleasant taste, they are taken with pleasure and give no toxic and allergic side effects.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000536:Aluminum Hydroxide / Q000627:therapeutic use*; D000863:Antacids / Q000627:therapeutic use*; D001566:Benzocaine / Q000627:therapeutic use; D002031:Bulgaria; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005753:Gastric Mucosa / Q000187:drug effects; D005782:Gels; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use*; D008276:Magnesium Hydroxide / Q000627:therapeutic use*; D008875:Middle Aged; D012828:Silicones / Q000627:therapeutic use*; D012833:Siloxanes / Q000627:therapeutic use*; D013012:Sorbitol / Q000627:therapeutic use*; D013997:Time Factors
D000863:Antacids; D004338:Drug Combinations; D005782:Gels; D012828:Silicones; D012833:Siloxanes; C025068:aluminum hydroxide, benzocaine, magnesium hydroxide, sorbitol drug combination; C025067:aluminum hydroxide, magnesium hydroxide, sorbitol drug combination; D013012:Sorbitol; D000536:Aluminum Hydroxide; C025069:aluminum hydroxide, magnesium hydroxide, methylpolysiloxane, sorbitol drug combination; C025070:aluminum hydroxide - benzocaine - flatugel - magnesium hydroxide - methylpolysiloxane - sorbitol; D008274:Magnesium; D008276:Magnesium Hydroxide; D001566:Benzocaine
Klinichno izpitvane na bulgarskite preparati flatugel i almagel-neo pri bolni s duodenalna iazva.